Navigation Links
Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
Date:9/15/2008

- New data, updated since ASCO, show time without tumor growth now reaches

nearly 5 months with RAD001 vs. 1.9 months with placebo - One quarter of patients in trial remained progression-free beyond ten

months of treatment - RAD001 is first drug to show significant benefit after failure of initial therapy, Sutent(R) or Nexavar(R)**, with potential to address unmet medical

need - RAD001 under review by regulatory authorities; potential to be first

once-daily oral mTOR therapy for advanced kidney cancer

EAST HANOVER, N.J., Sept. 16 /PRNewswire-FirstCall/ -- New data continue to demonstrate the potential benefit of RAD001 (everolimus) for patients with advanced kidney cancer who have failed standard therapies.

Updated study findings from the RECORD-1 (REnal Cell cancer treatment with Oral RAD001 given Daily) study show that patients receiving RAD001 had no tumor growth for nearly 5 months vs. 1.9 months for patients receiving placebo (hazard ratio = 0.33 with 95% CI 0.25 to 0.43; p-value < 0.001). In addition, after more than 10 months of treatment with RAD001, 25% of patients still had no tumor growth.

The updated RECORD-1 data were presented today at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, Sweden.

"These study results show the potential of RAD001 to continue working over an extended period of time in patients with advanced kidney cancer that progressed despite treatment with standard therapies," said Bernard Escudier, MD, Head of Immunotherapy and Innovative Therapy Unit, Gustave-Roussy Institute, Paris, France. "Based on these findings, I believe RAD001 should become part of the treatment paradigm for this patient population."

RAD001 has the potential to fill a currently unmet medical need and become the first approved therapy to demonstrate significant benefit in patients with advanced kidney ca
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
2. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
3. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
4. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
5. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
6. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
7. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
8. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
9. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
10. Most Cancer Treatment Studies Arent Published, Study Finds
11. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 Transportation Insight, a leading global ... client, DSI Systems Inc., are featured in the ... in the cover story emphasizing technology as the ... editorial illustrates how Transportation Insight implemented its ... growth and success of DSI,s complex supply chain. ...
(Date:5/4/2015)... , May 4, 2015 DePuy Synthes CMF* ... Repair, the first commercially available biosynthesized dural replacement derived ... is a part of the DePuy Synthes Companies of ... tissue membrane that covers and protects the brain and ... to allow surgeons to access the brain. A dural ...
(Date:5/4/2015)... -- The board of directors of Eli Lilly and Company (NYSE: ... quarter of 2015 of $0.50 per share on outstanding common ... 2015, to shareholders of record at the close of business ... Lilly is a global healthcare leader that unites caring with ... We were founded more than a century ago by a ...
Breaking Medicine Technology:Transportation Insight's Latest Enterprise Logistics Technology Highlighted in Inbound Logistics Magazine 2Transportation Insight's Latest Enterprise Logistics Technology Highlighted in Inbound Logistics Magazine 3DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 3
... BOZEN, Sud-Tirol, Italy , July 20, 2010 ... rights in Spain and Portugal to world-leading IV,Therapy company ... at Vall d,Hebron University Hospital in Barcelona in November,2010 . ... "We are ...
... , WILMINGTON, Del. , July 20 ... Be Heard… Living With Depression contest, ... Bipolar Support Alliance (DBSA), encourages people with depressive symptoms of ... depression) to share their stories of success.  Submissions are now ...
Cached Medicine Technology:Health Robotics' CytoCare Continues European Expansion With Grifols and Vall d'Hebron University Hospital 2Health Robotics' CytoCare Continues European Expansion With Grifols and Vall d'Hebron University Hospital 3Health Robotics' CytoCare Continues European Expansion With Grifols and Vall d'Hebron University Hospital 4National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 2National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 3National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 4National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 5National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 6National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 7
(Date:5/4/2015)... Malibu Biotech Systems LLC salutes ... KissSafe™ is the first personal hygiene product dedicated ... adding fresh breath appeal. KissSafe™ contains an FDA-approved ... in the mouth and oral cavity before and ... possess additional wellness benefits. KissSafe’s proprietary prevent-tech will ...
(Date:5/4/2015)... In a continuing effort to remain a leading ... the founder of Choices Recovery in South Bend, IN, ... the Oscars” celebration held on February 21st, 2015, ... the luxurious Beverly Hilton Hotel. , Organized by ... placement in TV and film, this daylong event gathered ...
(Date:5/4/2015)... 04, 2015 Takeda Pharmaceuticals Corp. has ... settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) ... risk that a patient will develop bladder cancer. According ... 95% of those eligible for the Actos settlement accept ... cancer cases currently pending in courts around the country, ...
(Date:5/4/2015)... California (PRWEB) May 04, 2015 Getting ... to manage their health is critical to achieving the ... and reducing costs, but this will require a shift ... change also demands that health systems move beyond their ... who took part in the third live meeting of ...
(Date:5/4/2015)... TROY Healthcare Solutions is proud to be a ... (RUG) Conference in Baltimore, MD from May 11 – ... provides an opportunity for clients to gather to network, ... In addition to sponsoring the event, TROY Healthcare Solutions ... Conference. Attendees can stop by the TROY booth and ...
Breaking Medicine News(10 mins):Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Per Wickstrom Interviews TV and Film Star Carolyn Hennesy About Substance Abuse and Treatment 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 4Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3
... , TAMPA, Fla., Nov. 4 ... today its SNP Model of Care program to assist Special ... Medicare Improvements for Patients and Providers Act of 2008 (MIPPA). ... with Health Integrated will install a cost-effective, rapidly deployable program ...
... New ... orthopedic and sport uses. , ... San Diego, CA (PRWEB) November 4, 2009 -- BetterBraces.com, the sports bracing ... The new site continues BetterBraces.com commitment to provide customers with top quality braces and ...
... successes, especially for those with good lung function , ... 100 percent for people with early-stage lung cancer and ... radiosurgery using CyberKnife, according to a new study funded ... people with small lung tumors calls for surgical removal ...
... NEW YORK, Nov. 4 Vitech Systems Group, ... benefits administration, announced today that the Milwaukee County ... Vitech,s web-based customer self-service solution. This new self-service ... retired employees of Milwaukee County to receive real-time ...
... study accepted for publication in The Endocrine Society,s Journal ... quickly, as compared to slowly, curtails the release of hormones ... The decreased release of these hormones, can often lead to ... can lead to food overconsumption and obesity, and in fact ...
... ... On Mandatory Sleep Apnea Testing And "Successful Treatment", It Is Practically ... More Than 60% Of Sleep Apnea Patients Can Not Tolerate The ... Commercial Pilots And Drivers May Forever Lose Their Pilot,s Or Driver,s ...
Cached Medicine News:Health News:Health Integrated Announces Turnkey Model of Care Program for Special Needs Health Plans 2Health News:Health Integrated Announces Turnkey Model of Care Program for Special Needs Health Plans 3Health News:The Sports Bracing and Therapy Experts Re-Launch Website BetterBraces.com 2Health News:Focused Radiation May Help Some With Lung Cancer 2Health News:Milwaukee County Employees' Retirement System (MCERS) Goes Live with V3 Self-Service 2Health News:New scientific study indicates that eating quickly is associated with overeating 2Health News:SleepApneaUSA.net Announced An Alternative Sleep Apnea Solution For Commercial Pilots After NTSB Recommended Mandatory Sleep Apnea Certification For Testing And 'Successful Treatment' 2Health News:SleepApneaUSA.net Announced An Alternative Sleep Apnea Solution For Commercial Pilots After NTSB Recommended Mandatory Sleep Apnea Certification For Testing And 'Successful Treatment' 3Health News:SleepApneaUSA.net Announced An Alternative Sleep Apnea Solution For Commercial Pilots After NTSB Recommended Mandatory Sleep Apnea Certification For Testing And 'Successful Treatment' 4Health News:SleepApneaUSA.net Announced An Alternative Sleep Apnea Solution For Commercial Pilots After NTSB Recommended Mandatory Sleep Apnea Certification For Testing And 'Successful Treatment' 5
... Supplemental Confirmatory (Western Blot): The Genetic Systems ... test for the detection of antibodies to HIV-1. ... strain of HIV-1 grown in the CEM cell ... is devoid of HLA Class ll antigens, helps ...
... Screening: The Procleix System has added ... the nation's blood supply. It utilizes innovative ... and a unique nucleic acid amplification technique ... can simultaneously detect the presence of HIV-1 ...
... Diagnostic, Non-Donor Screen. Vironostika HIV assays provide ... additional testing and confirmation. Vironostika HIV-1 ... for the detection of antibody to HIV-1 ... Oral Fluid Vironostika HIV-1 Microelisa System ...
... an OraSure HIV-1 Oral Specimen Collection Device is ... for HIV-1 antibodies. Testing with the OraSure HIV-1 ... needles and has been shown to be more ... specially treated cotton fiber pad attached to a ...
Medicine Products: